177 related articles for article (PubMed ID: 23012621)
1. Persistence versus reversion of 3TC resistance in HIV-1 determine the rate of emergence of NVP resistance.
Rath BA; Olshen RA; Halpern J; Merigan TC
Viruses; 2012 Aug; 4(8):1212-34. PubMed ID: 23012621
[TBL] [Abstract][Full Text] [Related]
2. Low rate of emergence of nevirapine and lamivudine resistance after post-partum interruption of a triple-drug regimen.
Pérez H; Vignoles M; Laufer N; Gómez A; Coll P; Lottner J; Rolón M; Salomón H; Cahn P
Antivir Ther; 2008; 13(1):135-9. PubMed ID: 18389908
[TBL] [Abstract][Full Text] [Related]
3. Measuring enzymatic HIV-1 susceptibility to two reverse transcriptase inhibitors as a rapid and simple approach to HIV-1 drug-resistance testing.
Hoffmann D; Garcia AD; Harrigan PR; Johnston IC; Nakasone T; García-Lerma JG; Heneine W
PLoS One; 2011; 6(7):e22019. PubMed ID: 21799767
[TBL] [Abstract][Full Text] [Related]
4. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF
Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391
[TBL] [Abstract][Full Text] [Related]
5. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of 3TC in HIV clinical trials may be due in part to the M184V substitution in 3TC-resistant HIV-1 reverse transcriptase.
Wainberg MA; Hsu M; Gu Z; Borkow G; Parniak MA
AIDS; 1996 Dec; 10 Suppl 5():S3-10. PubMed ID: 9030390
[TBL] [Abstract][Full Text] [Related]
7. Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens.
Svicher V; Alteri C; Artese A; Forbici F; Santoro MM; Schols D; Van Laethem K; Alcaro S; Costa G; Tommasi C; Zaccarelli M; Narciso P; Antinori A; Ceccherini-Silberstein F; Balzarini J; Perno CF
J Acquir Immune Defic Syndr; 2010 Nov; 55(3):336-44. PubMed ID: 20739898
[TBL] [Abstract][Full Text] [Related]
8. Competitive capacity of HIV-1 strains carrying M184I or Y181I drug-resistant mutations.
Li J; Li L; Li HP; Zhuang DM; Liu SY; Liu YJ; Bao ZY; Wang Z; Li JY
Chin Med J (Engl); 2009 May; 122(9):1081-6. PubMed ID: 19493444
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients.
Ribera E; Rodríguez-Pardo D; Rubio M; Soler A; Pedrol E; Blanco JL; González A; Crespo M; Falcó V; Ocaña I; Deig E; Miró JM; Pahissa A
Antivir Ther; 2005; 10(5):605-14. PubMed ID: 16152754
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of short-course AZT plus 3TC to reduce nevirapine resistance in the prevention of mother-to-child HIV transmission: a randomized clinical trial.
McIntyre JA; Hopley M; Moodley D; Eklund M; Gray GE; Hall DB; Robinson P; Mayers D; Martinson NA
PLoS Med; 2009 Oct; 6(10):e1000172. PubMed ID: 19859531
[TBL] [Abstract][Full Text] [Related]
11. Combination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine.
Gatanaga H; Ode H; Hachiya A; Hayashida T; Sato H; Oka S
Antimicrob Agents Chemother; 2010 Apr; 54(4):1596-602. PubMed ID: 20124001
[TBL] [Abstract][Full Text] [Related]
12. Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377).
Eshleman SH; Krogstad P; Jackson JB; Wang YG; Lee S; Wei LJ; Cunningham S; Wantman M; Wiznia A; Johnson G; Nachman S; Palumbo P
J Infect Dis; 2001 Jun; 183(12):1732-8. PubMed ID: 11372025
[TBL] [Abstract][Full Text] [Related]
13. Antiretroviral drug-resistant mutations at baseline and at time of failure of antiretroviral therapy in HIV type 1-coinfected TB patients.
Rajesh L; Karunaianantham R; Narayanan PR; Swaminathan S
AIDS Res Hum Retroviruses; 2009 Nov; 25(11):1179-85. PubMed ID: 19895208
[TBL] [Abstract][Full Text] [Related]
14. A rapid non-culture-based assay for clinical monitoring of phenotypic resistance of human immunodeficiency virus type 1 to lamivudine (3TC).
García Lerma J; Schinazi RF; Juodawlkis AS; Soriano V; Lin Y; Tatti K; Rimland D; Folks TM; Heneine W
Antimicrob Agents Chemother; 1999 Feb; 43(2):264-70. PubMed ID: 9925516
[TBL] [Abstract][Full Text] [Related]
15. Polymorphisms and drug resistance analysis of HIV-1 CRF01_AE strains circulating in Fujian Province, China.
Liu J; Yue J; Wu S; Yan Y
Arch Virol; 2007; 152(10):1799-805. PubMed ID: 17619115
[TBL] [Abstract][Full Text] [Related]
16. Emergence of minor drug-resistant HIV-1 variants after triple antiretroviral prophylaxis for prevention of vertical HIV-1 transmission.
Hauser A; Sewangi J; Mbezi P; Dugange F; Lau I; Ziske J; Theuring S; Kuecherer C; Harms G; Kunz A
PLoS One; 2012; 7(2):e32055. PubMed ID: 22384138
[TBL] [Abstract][Full Text] [Related]
17. Lamivudine resistance of HIV type 1 does not delay development of resistance to nonnucleoside HIV type 1-specific reverse transcriptase inhibitors as compared with wild-type HIV type 1.
Jonckheere H; Witvrouw M; De Clercq E; Anné J
AIDS Res Hum Retroviruses; 1998 Feb; 14(3):249-53. PubMed ID: 9491915
[TBL] [Abstract][Full Text] [Related]
18. Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy.
Kamya MR; Mayanja-Kizza H; Kambugu A; Bakeera-Kitaka S; Semitala F; Mwebaze-Songa P; Castelnuovo B; Schaefer P; Spacek LA; Gasasira AF; Katabira E; Colebunders R; Quinn TC; Ronald A; Thomas DL; Kekitiinwa A;
J Acquir Immune Defic Syndr; 2007 Oct; 46(2):187-93. PubMed ID: 17693883
[TBL] [Abstract][Full Text] [Related]
19. Greater suppression of nevirapine resistance with 21- vs 7-day antiretroviral regimens after intrapartum single-dose nevirapine for prevention of mother-to-child transmission of HIV.
McMahon DK; Zheng L; Hitti J; Chan ES; Halvas EK; Hong F; Kabanda J; Taulo F; Kumarasamy N; Bonhomme J; Wallis CL; Klingman KL; Hughes MD; Mellors JW
Clin Infect Dis; 2013 Apr; 56(7):1044-51. PubMed ID: 23300238
[TBL] [Abstract][Full Text] [Related]
20. Zidovudine/lamivudine but not nevirapine in combination with lopinavir/ritonavir decreases subcutaneous adipose tissue mitochondrial DNA.
Feeney ER; van Vonderen MG; Wit F; Danner SA; van Agtmael MA; Villarroya F; Domingo P; Capeau J; Reiss P; Mallon PW;
AIDS; 2012 Nov; 26(17):2165-74. PubMed ID: 22874517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
